
Sexual dysfunction, Peyronie’s research centers on medical therapies
In the area of sexual dysfunction, much of the clinical research continues to focus on medical therapies, and this will be evident at the upcoming AUA annual meeting in San Diego.
This article is part of the
In the area of sexual dysfunction, much of the clinical research continues to focus on medical therapies, and this will be evident at the upcoming AUA annual meeting in San Diego. In addition, cardiovascular screening in patients presenting with erectile dysfunction remains a high-interest topic, said John J. Mulcahy, MD, PhD, a sexual medicine specialist in private practice in Madison, AL.


Dr. Mulcahy also suggests that AUA attendees watch for new research on collagenase clostridium histolyticum (XIAFLEX) as a treatment for men with Peyronie’s disease. The data are timely, as the FDA has accepted for filing the supplemental biologics license application for this agent and is expected to take action on the application by Sept. 6, 2013. Expect new research findings on priapism and its treatment, Dr. Mulcahy added.
His specific abstract recommendations are as follows:
Larry Lipshultz
Irwin Goldstein
Wayne Hellstrom
Culley Carson, III
Christopher McMahon
Charles Welliver
Seth D. Cohen
Raanan Tal
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.






















